UAE Attention Deficit Hyperactivity Disorder Therapeutic Market Report 2022 to 2030

UAE ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

UAE's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $148 Mn in 2022 to $284 Mn in 2030 with a CAGR of 8.5% for the year 2022-30. More cases of ADHD being diagnosed in children and UAE and the development of health infrastructure in UAE are the main market drivers. The UAE ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Join Hub Gulf Pharma, Genpharm, and Eli Lilly are some of the key players in the market.

ID: IN10AEPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Parul Choudhary

Buy Now

UAE Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The UAE Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $148 Mn in 2022 and is projected to reach $284 Mn in 2030, exhibiting a CAGR of 8.5% during the forecast period. Dubai's budget for 2023 maintains its emphasis on social services as well as the growth of the health, education, and cultural industries. A total of 34 % of total government expenditures of the 2023 budget goes to the social development sector in the areas of health, education, scientific research, housing, care for needy families and women and children, reading, translation and programming initiatives, development of youth and sports, care for senior citizens and retirees and care for people of determination. Spending in this category has increased by 4% since the estimate for 2022. Last year, the cabinet approved a $79 Bn budget for the 2022-26 period, the largest five-year federal budget, with a strong focus on the development of sectors such as healthcare, education, and pensions.

When a person has ADHD, their brain develops and functions differently, which affects their focus and can lead to hyperactivity and impulsivity. The pediatric incidence of ADHD is thought to be between 5 and 10% globally and 4-5% in the UAE. A diagnosis of ADHD can have an immense impact on an individual's life. Children may experience scholastic limitations as well as social and family dynamics as a result. It can impact a child's self-esteem as they enter adolescence and result in difficulties with their career and employment as adults.

In the past, medication and counseling or instruction for parents were common forms of ADHD treatment in Dubai. It makes sense, though, that parents might be hesitant to offer their kids ADHD medication. When it comes to wanting better approaches to treating their children's ADHD, parents in the UAE are not an exception. One of the cornerstones of therapy for ADHD is medication. The most typical class of medicine used by psychiatrists to treat ADHD is stimulant medication. It might seem strange to use stimulant medication to address hyperactivity. However, patients with ADHD actually experience a calming impact from this medication. There is only one stimulant and one non-stimulant drug accessible in Dubai. Stimulant medicines like amphetamines and methylphenidate are frequently prescribed for ADHD in Dubai.

uae attention deficit hyperactivity disorders therapeutics market analysis

Market Dynamics

Market Growth Drivers

More children are likely to receive an ADHD diagnosis as awareness of the condition grows among parents, educators, and medical workers. This will increase demand for therapies such as ADHD medication. Hospitals, clinics, and medical schools are just a few of the healthcare facilities in the UAE that have recently benefited from substantial investments. For people with ADHD, this will increase access to healthcare services and spur the UAE ADHD therapeutics market expansion.

Market Restraints

In the UAE, there is still a sizable shame attached to mental health conditions, including ADHD. This might make parents less likely to have their kids diagnosed and treated, which might slow the expansion of the industry. Although some insurance providers in the UAE do cover ADHD medicines and treatments, coverage is frequently constrained or non-existent. This may restrict market expansion and make treatment unaffordable for many families. Alternative therapies for ADHD, like behavioral therapy or dietary modifications, may be preferred by some parents, which could reduce the need for medication and other conventional treatments. This may restrict the UAE ADHD therapeutics market expansion.

Competitive Landscape

Key Players

MPC Healthcare (ARE)
Mundipharma (ARE)
Hospira (ARE)
Join Hub Gulf Pharma (ARE)
Genpharm (ARE)
Eli Lilly
Perdue Pharma
Johnson and Johnson
Janssen
Takeda
GlaxoSmithKline

Healthcare Policies and Regulatory Landscape

The government health agency in charge of delivering medical services is the Ministry of Health and Prevention. Similar duties are carried out by the Department of Health – Abu Dhabi, Dubai Health Authority (DHA), and Sharjah Health Authority in the emirates of Abu Dhabi, Dubai, and Sharjah, respectively. The main body in charge of regulating all aspects of the pharmaceutical industry in the UAE is the Ministry of Health (MOH). In addition to managing the healthcare industry in the Northern Emirates, the Ministry of Health develops the UAE's national medical and healthcare strategy. Market licenses issued by foreign governments are not accepted in the UAE and cannot be applied for there. The Ministry of Health must grant the necessary licenses and authorizations to any entities planning to trade or market their products. It should be noted, though, that a foreign business may employ a local distributor or agent who has already obtained a MOH license.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.